Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Review ArticleClinical Review

MALAdaptive: Do We Avoid Metformin Unnecessarily?

Chris Terpening
The Journal of the American Board of Family Medicine January 2014, 27 (1) 136-141; DOI: https://doi.org/10.3122/jabfm.2014.01.120173
Chris Terpening
From the Departments of Family Medicine and Clinical Pharmacy, West Virginia University, Charleston.
PhD, PharmD, BCACP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    CDC's Division of Diabetes Translation. Long-term trends in diagnosed diabetes. Atlanta: Centers for Disease Control; 2011. Available from: http://www.cdc.gov/diabetes/statistics/slides/long_term_trends.pdf. Accessed November 8, 2013.
  2. 2.↵
    1. Inzucchi SE,
    2. Bergenstal RM,
    3. Buse JB,
    4. et al
    . Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 2012;35:1364–79.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Handelsman Y,
    2. Mechanick J,
    3. Blonde L,
    4. et al
    . American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract 2011;17:287–302.
    OpenUrlCrossRefPubMed
  4. 4.↵
    UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Holman RR,
    2. Paul SK,
    3. Bethel MA,
    4. Matthews DR,
    5. Neil HAW
    . 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Metformin package insert. Princeton, NJ: Bristol-Myers Squibb; 2008.
  7. 7.↵
    1. Luft D,
    2. Deichsel G,
    3. Schmulling R,
    4. Stein W,
    5. Eggstein M
    . Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol 1983;80:484–9.
    OpenUrlPubMedWeb of Science
  8. 8.↵
    1. Stacpoole PW,
    2. Wright EC,
    3. Baumgartner TG,
    4. et al
    . Natural history and course of acquired lactic acidosis in adults. Am J Med 1994;97:47–54.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. McCormack J,
    2. Johns K,
    3. Tildesley H
    . Metformin's contraindications should be contraindicated. CMAJ 2005;173:502–4.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Heaf JG,
    2. van Biesen W
    . Metformin and chronic renal impairment: a story of choices and ugly ducklings. Clin Diabetes 2011;29:97–101.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Holstein A,
    2. Stumvoll M
    . Contraindications can damage your health—is metformin a case in point? Diabetologia 2005;48:2454–59.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Philbrick AM,
    2. Ernst ME,
    3. McDanel DL,
    4. Ross MB,
    5. Moores KG
    . Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? Am J Health Syst Pharm 2009;66:2017–22.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Lalau J-D
    . Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010;33:727–40.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Salpeter SR,
    2. Greyber E,
    3. Pasternak GA,
    4. Salpeter EE
    . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;(4):CD002967.
  15. 15.↵
    1. Duong JK,
    2. Roberts DM,
    3. Furlong TJ,
    4. et al
    . Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012;14:963–65.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Wills BK,
    2. Bryant SM,
    3. Buckley P,
    4. Seo B
    . Can acute overdose of metformin lead to lactic acidosis? Am J Emerg Med 2010;28:857–61.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Lalau JD,
    2. Mourlhon C,
    3. Bergeret A,
    4. Lacroix C
    . Consequences of metformin intoxication. Diabetes Care 1998;21:2036–7.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Stades AME,
    2. Heikens JT,
    3. Erkelens DW,
    4. Holleman F,
    5. Hoekstra JBL
    . Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004;255:179–87.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. van Berlo-van de Laar IRF,
    2. Vermeij CG,
    3. Doorenbos CJ
    . Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011;36:376–82.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Duong JK,
    2. Furlong TJ,
    3. Roberts DM,
    4. et al
    . The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis. Drug Saf 2013 Apr 3. [Epub ahead of print]
  21. 21.↵
    1. Kajbaf F,
    2. Lalau J-D
    . The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. BMC Pharm Toxicol 2013;14:22.
    OpenUrl
  22. 22.↵
    1. Seidowsky A,
    2. Nseir S,
    3. Houdret N,
    4. Fourrier F
    . Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009;37:2191–6.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Lalau J-D,
    2. Race JM
    . Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999;20:377–84.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Friesecke S,
    2. Abel P,
    3. Roser M,
    4. Felix S,
    5. Runge S
    . Outcome of severe lactic acidosis associated with metformin accumulation. Crit Care 2010;14:R226.
    OpenUrlPubMed
  25. 25.↵
    1. Peters N,
    2. Jay N,
    3. Barraud D,
    4. et al
    . Metformin-associated lactic acidosis in an intensive care unit. Crit Care 2008;12:R149.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Renda F,
    2. Mura P,
    3. Finco G,
    4. Ferrazin F,
    5. Pani L,
    6. Landoni G
    . Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci 2013;17(Suppl 1):45–9.
    OpenUrlPubMed
  27. 27.↵
    1. Kajbaf F,
    2. Lalau JD
    . The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med 2013;30:345–8.
    OpenUrlPubMed
  28. 28.↵
    1. Brown JB,
    2. Pedula K,
    3. Barzilay J,
    4. Herson MK,
    5. Latare P
    . Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659–63.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Cryer DR,
    2. Nicholas SP,
    3. Henry DH,
    4. Mills DJ,
    5. Stadel BV
    . Comparative outcomes study of metformin intervention versus conventional approach: The COSMIC Approach Study. Diabetes Care 2005;28:539–43.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Bodmer M,
    2. Meier C,
    3. Krähenbühl S,
    4. Jick SS,
    5. Meier CR
    . Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care 2008;31:2086–91.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Kamber N,
    2. Davis WA,
    3. Bruce DG,
    4. Davis TME
    . Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med J Austr 2008;188:446–9.
    OpenUrl
  32. 32.↵
    1. Stang M,
    2. Wysowski DK,
    3. Butler-Jones D
    . Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925–7.
    OpenUrlAbstract
  33. 33.↵
    1. Scott KA,
    2. Martin JH,
    3. Inder WJ
    . Acidosis in the hospital setting: is metformin a common precipitant? Intern Med J 2010;40:342–6.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Scale T,
    2. Harvey JN
    . Diabetes, metformin and lactic acidosis. Clin Endocrinol 2011;74:191–6.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Hloch O,
    2. Charvat J,
    3. Masopust J,
    4. Havlin J
    . Lactic acidosis in medical ICU–the role of diabetes mellitus and metformin. Neuro Endocrinol Lett 2012;33:792–5.
    OpenUrlPubMed
  36. 36.↵
    1. Bruijstens LA,
    2. van Luin M,
    3. Buscher-Jungerhans PM,
    4. Bosch FH
    . Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med 2008;66:185–90.
    OpenUrlPubMedWeb of Science
  37. 37.↵
    1. Vecchio S,
    2. Protti A
    . Metformin-induced lactic acidosis: no one left behind. Crit Care 2011;15:107.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Emslie-Smith AM,
    2. Boyle DIR,
    3. Evans JMM,
    4. Sullivan F,
    5. Morris AD
    ; DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with Type 2 diabetes—a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483–8.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Pongwecharak J,
    2. Tengmeesri N,
    3. Malanusorn N,
    4. Panthong M,
    5. Pawangkapin N
    . Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome Pharm World Sci 2009;31:481–6.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Tahrani AA,
    2. Varughese GI,
    3. Scarpello JH,
    4. Hanna FWF
    . Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007;335:508–12.
    OpenUrlFREE Full Text
  41. 41.↵
    1. Meyers JL,
    2. Candrilli SD,
    3. Kovacs B
    . Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011;123:133–43.
    OpenUrlPubMed
  42. 42.↵
    1. Rachmani R,
    2. Slavachevski I,
    3. Levi Z,
    4. Zadok B-S,
    5. Kedar Y,
    6. Ravid M
    . Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002;13:428–33.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Roussel R,
    2. Travert F,
    3. Pasquet B,
    4. et al
    . Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892–9.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Ekström N,
    2. Schiöler L,
    3. Svensson A-M,
    4. et al
    . Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012;2:e001076.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 27 (1)
The Journal of the American Board of Family Medicine
Vol. 27, Issue 1
January-February 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MALAdaptive: Do We Avoid Metformin Unnecessarily?
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
MALAdaptive: Do We Avoid Metformin Unnecessarily?
Chris Terpening
The Journal of the American Board of Family Medicine Jan 2014, 27 (1) 136-141; DOI: 10.3122/jabfm.2014.01.120173

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MALAdaptive: Do We Avoid Metformin Unnecessarily?
Chris Terpening
The Journal of the American Board of Family Medicine Jan 2014, 27 (1) 136-141; DOI: 10.3122/jabfm.2014.01.120173
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Metformin Serum Concentrations and Lactic Acidosis
    • Population Studies
    • Contraindications
    • Conclusions and Recommendations
    • Notes
    • References
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Family Physicians are Complex Care Physicians and Quality of Care Advancement Experts
  • Google Scholar

More in this TOC Section

  • Interpretating Normal Values and Reference Ranges for Laboratory Tests
  • Non-Surgical Management of Urinary Incontinence
  • Screening and Diagnosis of Type 2 Diabetes in Sickle Cell Disease
Show more Clinical Review

Similar Articles

Keywords

  • Diabetes Mellitus
  • Lactic Acidosis
  • Metformin

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire